SC
ELV icon

Scholtz & Company’s Elevance Health ELV Stock Holding History

Scholtz & Company’s Portfolio ELV Stock Details ELV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-4,827
Closed -$2.51M – 52
2024
Q3 		$2.51M Buy
4,827
+30
+0.6% +$16K 1.18% 26
2024
Q2 		$2.6M Sell
4,797
-74
-2% -$39.1K 1.11% 29
2024
Q1 		$2.53M Sell
4,871
-1,760
-27% -$875K 1.11% 28
2023
Q4 		$3.13M Sell
6,631
-793
-11% -$367K 1.55% 24
2023
Q3 		$3.23M Sell
7,424
-1,281
-15% -$581K 2.13% 22
2023
Q2 		$3.87M Sell
8,705
-84
-1% -$38.8K 2.42% 15
2023
Q1 		$4.04M Sell
8,789
-198
-2% -$94.2K 2.89% 13
2022
Q4 		$4.61M Sell
8,987
-76
-0.8% -$38.6K 3.26% 11
2022
Q3 		$4.45M Buy
9,063
+491
+6% +$235K 3.18% 10
2022
Q2 		$4.14M Buy
+8,572
New +$4.24M 2.54% 13

Other funds holding ELV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Sanders Capital
Sanders Capital West Palm Beach, Florida $83.9B AUM 37.89% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Scholtz & Company's ELV Position: Q4 2024 in Review

Scholtz & Company sold out of Elevance Health (ELV) in Q4 2024, closing a stake of 4,827 shares — an estimated $2.51M sold.

Scholtz & Company first reported a position in ELV in Q2 2022 and held it in 10 quarters. The position peaked at $4.61M in Q4 2022. 1,602 funds tracked by Wall St. Rank hold ELV as of Q4 2024.

  • Scholtz & Company reported no remaining Elevance Health position as of Q4 2024 after selling out during the quarter.
  • Scholtz & Company sold 4,827 Elevance Health shares in Q4 2024, an estimated $2.51M.
  • Scholtz & Company first reported a position in Elevance Health in Q2 2022 and held it in 10 quarters.
  • Scholtz & Company's Elevance Health position peaked at $4.61M in Q4 2022.
  • 1,602 funds tracked by Wall St. Rank held Elevance Health as of Q4 2024.

Based on Scholtz & Company's 13F filing for Q4 2024, filed 12 Feb 2025.